Survey of Ophthalmology
Volume 54, Issue 6 , Pages 643-662 , November 2009

Understanding the Importance of IOP Variables in Glaucoma: A Systematic Review

  • Marla B. Sultan, MD, MBA

      Affiliations

    • New York Eye & Ear Infirmary, New York, New York, USA
    • Pfizer Inc, New York, New York, USA
    • Corresponding Author InformationReprint address: Marla B. Sultan, MD, MBA, Global Clinical Head, Ophthalmology, Pfizer Inc, 235 East 42nd Street, 219/8/97, New York, New York 10017.
    • ,
  • Steven L. Mansberger, MD

      Affiliations

    • Devers Eye Institute, Legacy Health System, Portland, Oregon, USA
    • ,
  • Paul P. Lee, MD, JD

      Affiliations

    • Glaucoma Service, Duke University Eye Center, Durham, North Carolina, USA

References 

  1. Agarwal HC, Sihota R, Das C, Dada T. Role of argon laser trabeculoplasty as primary and secondary therapy in open angle glaucoma in Indian patients. Br J Ophthalmol. 2002;86(7):733–736
  2. AGIS (Advanced Glaucoma Intervention Study) Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440
  3. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102(12):1743–1752
  4. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78(1):71–76
  5. American Academy of Ophthalmology. Basic and Clinical Science Course. San Francisco, CA: American Academy of Ophthalmology; 2006;
  6. American Academy of Ophthalmology Preferred Practice Patterns Committee Glaucoma Panel. Preferred Practice Pattern. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2003;
  7. Anderson DR, Grant WM. The influence of position on intraocular pressure. Invest Ophthalmol Vis Sci. 1973;12(3):204–212
  8. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142
  9. Barkana Y, Anis S, Liebmann J, et al. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006;124(6):793–797
  10. Bengtsson B, Heijl A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):513–518
  11. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106(5):997–1004
  12. Bhan A, Bhargava J, Vernon SA, et al. Repeatability of ocular blood flow pneumotonometry. Ophthalmology. 2003;110(8):1551–1554
  13. Bhan A, Browning AC, Shah S, et al. Effect of corneal thickness on intraocular pressure measurements with the pneumotonometer, Goldmann applanation tonometer, and Tono-Pen. Invest Ophthalmol Vis Sci. 2002;43(5):1389–1392
  14. Boothe WA, Lee DA, Panek WC, et al. The Tono-Pen. A manometric and clinical study. Arch Ophthalmol. 1988;106(9):1214–1217
  15. Brandt JD, Beiser JA, Gordon MO, et al. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004;138(5):717–722
  16. Browning AC, Bhan A, Rotchford AP, et al. The effect of corneal thickness on intraocular pressure measurement in patients with corneal pathology. Br J Ophthalmol. 2004;88(11):1395–1399
  17. Burgoyne CF, Downs JC, Bellezza AJ, et al. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res. 2005;24(1):39–73
  18. Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103(11):1916–1924
  19. Collaborative Initial Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497
  20. Collaborative Initial Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505
  21. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–485
  22. Congdon NG, Broman AT, Bandeen-Roche K, et al. Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol. 2006;141(5):868–875
  23. Copt RP, Thomas R, Mermoud A. Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. Arch Ophthalmol. 1999;117(1):14–16
  24. Daugeliene L, Yamamoto T, Kitazawa Y. Effect of trabeculectomy on visual field in progressive normal-tension glaucoma. Jpn J Ophthalmol. 1998;42(4):286–292
  25. Diestelhorst M, Krieglstein GK. The effect of the water-drinking test on aqueous humor dynamics in healthy volunteers. Graefes Arch Clin Exp Ophthalmol. 1994;232(3):145–147
  26. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000;44(5):367–408
  27. Drance SM. Diurnal variation of intraocular pressure in treated glaucoma. Significance in patients with chronic simple glaucoma. Arch Ophthalmol. 1963;70:302–311
  28. Ehlers N, Bramsen T, Sperling S. Applanation tonometry and central corneal thickness. Acta Ophthalmol Scand. 1975;53(1):34–43
  29. Eisenberg DL, Sherman BG, McKeown CA, et al. Tonometry in adults and children. A manometric evaluation of pneumotonometry, applanation, and Tono-Pen in vitro and in vivo. Ophthalmology. 1998;105(7):1173–1181
  30. Esgin H, Alimgil ML, Erda S. Clinical comparison of the ocular blood flow tonograph and the Goldmann applanation tonometer. Eur J Ophthalmol. 1998;8(3):162–166
  31. Frankelson EN. The role of the water test in evaluation of glaucoma control. Can J Ophthalmol. 1974;9(4):408–410
  32. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532–538
  33. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110–121
  34. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414–422
  35. Gonzalez I, Pablo LE, Pueyo M, et al. Assessment of diurnal tensional curve in early glaucoma damage. Int Ophthalmol. 1997;20(1–3):113–115
  36. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–720discussion 829–30
  37. Grant WM, Burke JF. Why do some people go blind from glaucoma?. Ophthalmology. 1982;89(9):991–998
  38. Greenidge KC, Spaeth GL, Fiol-Silva Z. Effect of argon laser trabeculoplasty on the glaucomatous diurnal curve. Ophthalmology. 1983;90(7):800–804
  39. Gunvant P, Baskaran M, Vijaya L, et al. Effect of corneal parameters on measurements using the pulsatile ocular blood flow tonograph and Goldmann applanation tonometer. Br J Ophthalmol. 2004;88(4):518–522
  40. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105(11):2099–2104
  41. Heijl A, Bengtsson B. The short-term effect of laser trabeculoplasty on the glaucomatous visual field. A prospective study using computerized perimetry. Acta Ophthalmol Scand. 1984;62(6):705–714
  42. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279
  43. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol. 2004;122(1):17–21
  44. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120(7):915–922
  45. Horowitz GS, Byles J, Lee J, et al. Comparison of the Tono-Pen and Goldmann tonometer for measuring intraocular pressure in patients with glaucoma. Clin Exp Ophthalmol. 2004;32(6):584–589
  46. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12(3):232–236
  47. Jonas JB, Budde WM, Stroux A, et al. Diurnal intraocular pressure profiles and progression of chronic open-angle glaucoma. Eye. 2007;21(7):948–951
  48. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713discussion 829–30
  49. Kaufmann C, Bachmann LM, Robert YC, et al. Ocular pulse amplitude in healthy subjects as measured by dynamic contour tonometry. Arch Ophthalmol. 2006;124(8):1104–1108
  50. Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with Goldmann applanation tonometry. Invest Ophthalmol Vis Sci. 2004;45(9):3118–3121
  51. Kim JW, Chen PP. Central corneal pachymetry and visual field progression in patients with open-angle glaucoma. Ophthalmology. 2004;111(11):2126–2132
  52. Kniestedt C, Lin S, Choe J, et al. Clinical comparison of contour and applanation tonometry and their relationship to pachymetry. Arch Ophthalmol. 2005;123(11):1532–1537
  53. Kniestedt C, Nee M, Stamper RL. Accuracy of dynamic contour tonometry compared with applanation tonometry in human cadaver eyes of different hydration states. Graefes Arch Clin Exp Ophthalmol. 2005;243(4):359–366
  54. Ko YC, Liu CJI, Hsu WM. Varying effects of corneal thickness on intraocular pressure measurements with different tonometers. Eye. 2005;19(3):327–332
  55. Kohlhaas M, Boehm AG, Spoerl E, et al. Effect of central corneal thickness, corneal curvature, and axial length on applanation tonometry. Arch Ophthalmol. 2006;124(4):471–476
  56. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123(7):898–902
  57. Konstas AG, Kozobolis VP, Tersis I, et al. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye. 2003;17(1):41–46
  58. Konstas AG, Maltezos A, Bufidis T, et al. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye. 2000;14(1):73–77
  59. Konstas AG, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999;128(1):15–20
  60. Konstas AG, Mylopoulos N, Karabatsas CH, et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye. 2004;18(9):893–899
  61. Konstas AG, Topouzis F, Leliopoulou O, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology. 2006;113(5):761–765
  62. Kotecha A, White ET, Shewry JM, et al. The relative effects of corneal thickness and age on Goldmann applanation tonometry and dynamic contour tonometry. Br J Ophthalmol. 2005;89(12):1572–1575
  63. Kothy P, Vargha P, Hollo G. Ocuton-S self tonometry vs. Goldmann tonometry; a diurnal comparison study. Acta Ophthalmol Scand. 2001;79(3):294–297
  64. Laibovitz RA, Van Denburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001;119(7):994–1000
  65. Laiquzzaman M, Bhojwani R, Cunliffe I, et al. Diurnal variation of ocular hysteresis in normal subjects: relevance in clinical context. Clin Exp Ophthalmol. 2006;34(2):114–118
  66. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121(1):48–56
  67. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953
  68. Lim JI, Blair NP, Higginbotham MD, et al. Assessment of intraocular pressure in vitrectomized gas-containing eyes. A clinical and manometric comparison of the Tono-Pen to the pneumotonometer. Arch Ophthalmol. 1990;108(5):684–688
  69. Liu JH, Bouligny RP, Kripke DF, et al. Nocturnal elevation of intraocular pressure is detectable in the sitting position. Invest Ophthalmol Vis Sci. 2003;44(10):4439–4442
  70. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39(13):2707–2712
  71. Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40(12):2912–2917
  72. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389–395
  73. Liu JH, Zhang X, Kripke DF, et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci. 2003;44(4):1586–1590
  74. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111(1):51–55
  75. Martinez-Bello C, Chauhan BC, Nicolela MT, et al. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol. 2000;129(3):302–308
  76. Martinez-de-la-Casa JM, Garcia-Feijoo J, Fernandez-Vidal A, et al. Ocular response analyzer versus Goldmann applanation tonometry for intraocular pressure measurements. Invest Ophthalmol Vis Sci. 2006;47(10):4410–4414
  77. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999;106(3):550–555
  78. Medeiros FA, Pinheiro A, Moura FC, et al. Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. J Ocul Pharmacol Ther. 2002;18(6):489–498
  79. Medeiros FA, Sample PA, Weinreb RN. Corneal thickness measurements and frequency doubling technology perimetry abnormalities in ocular hypertensive eyes. Ophthalmology. 2003;110(10):1903–1908
  80. Medeiros FA, Sample PA, Zangwill LM, et al. Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol. 2003;136(5):805–813
  81. Medeiros FA, Weinreb RN. Evaluation of the influence of corneal biomechanical properties on intraocular pressure measurements using the ocular response analyzer. J Glaucoma. 2006;15(5):364–370
  82. Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235–243
  83. Miller D. The relationship between diurnal tension variation and the water-drinking test. Am J Ophthalmol. 1964;58:243–246
  84. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol. 2005;139(2):320–324
  85. Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1):37–44
  86. Nduaguba C, Lee RK. Glaucoma screening: current trends, economic issues, technology, and challenges. Curr Opin Ophthalmol. 2006;17(2):142–152
  87. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472–484
  88. Noël C, Kabo AM, Romanet JP, et al. Twenty-four-hour time course of intraocular pressure in healthy and glaucomatous Africans: relation to sleep patterns. Ophthalmology. 2001;108(1):139–144
  89. Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 2002;133(1):1–10
  90. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111(9):1627–1635
  91. O'Brien C, Schwartz B, Takamoto T, et al. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol. 1991;111(4):491–500
  92. Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol Scand. 1987;65:27–29
  93. Oliveira C, Tello C, Liebmann J, et al. Central corneal thickness is not related to anterior scleral thickness or axial length. J Glaucoma. 2006;15(3):190–194
  94. Oliver JE, Hattenhauer MG, Herman D, et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol. 2002;133(6):764–772
  95. Orssengo GJ, Pye DC. Determination of the true intraocular pressure and modulus of elasticity of the human cornea in vivo. Bull Math Biol. 1999;61(3):551–572
  96. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113(2):239–246
  97. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121(4):453–457
  98. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41(9):2566–2573
  99. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688–703
  100. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893–899
  101. Pizzarello L, Abiose A, Ffytche T, et al. VISION 2020: The Right to Sight: a global initiative to eliminate avoidable blindness. Arch Ophthalmol. 2004;122(4):615–620
  102. Roth JA. Inadequate diagnostic value of the water-drinking test. Br J Ophthalmol. 1974;58(1):55–61
  103. Sánchez-Tocino R, Bringas-Calvo R, Igleseas-Cortiñas D. Comparative study between the non-contact pneumotonometer Can TX10 and the Goldmann tonometer. Arch Soc Esp Oftalmol. 2005;80(11):643–649
  104. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115(7):847–852
  105. Shaarawy T, Flammer J, Haefliger IO. Reducing intraocular pressure: is surgery better than drugs?. Eye. 2004;18(12):1215–1224
  106. Shedden A, Laurence J, Tipping R. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther. 2001;23(3):440–450
  107. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368
  108. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin. 2005;21(4):503–508
  109. Sigal IA, Flanagan JG, Ethier CR. Factors influencing optic nerve head biomechanics. Invest Ophthalmol Vis Sci. 2005;46(11):4189–4199
  110. Singh RP, Goldberg I, Graham SL, et al. Central corneal thickness, tonometry, and ocular dimensions in glaucoma and ocular hypertension. J Glaucoma. 2001;10(3):206–210
  111. Sit AJ, Weinreb RN, Crowston JG, et al. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol. 2006;141(6):1131–1133
  112. Spraul CW, Lang GE, Ronzani M, et al. Reproducibility of measurements with a new slit lamp-mounted ocular blood flow tonograph. Graefes Arch Clin Exp Ophthalmol. 1998;236(4):274–279
  113. Stewart WC, Stewart JA, Day D, et al. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003;81(3):242–246
  114. Susanna R, Vessani RM, Sakata L, et al. The relation between intraocular pressure peak in the water drinking test and visual field progression in glaucoma. Br J Ophthalmol. 2005;89(10):1298–1301
  115. Theofylaktopoulos I, Diestelhorst M, Krieglstein GK. Self-tonometry with the Ocuton S versus Goldmann tonometry. Graefes Arch Clin Exp Ophthalmol. 1999;237:720–724
  116. Thomas R, Parikh R, George R, et al. Five-year risk of progression of ocular hypertension to primary open angle glaucoma. A population-based study. Indian J Ophthalmol. 2003;51(4):329–333
  117. Tomita G, Araie M, Kitazawa Y, et al. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye. 2004;18(10):984–989
  118. Tonnu PA, Ho T, Newson T, et al. The influence of central corneal thickness and age on intraocular pressure measured by pneumotonometry, non-contact tonometry, the Tono-Pen XL, and Goldmann applanation tonometry. Br J Ophthalmol. 2005;89(7):851–854
  119. Tonnu PA, Ho T, Sharma K, et al. A comparison of four methods of tonometry: method agreement and interobserver variability. Br J Ophthalmol. 2005;89(7):847–850
  120. Walker RE, Litovitz TL. An experimental and theoretical study of the pneumatic tonometer. Exp Eye Res. 1972;13(1):14–23
  121. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105(1):82–87
  122. Wax MB, Camras CB, Fiscella RG, et al. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol. 2002;133(Suppl):S1–S10
  123. Wilensky JT, Gieser DK, Mori MT, et al. Self-tonometry to manage patients with glaucoma and apparently controlled intraocular pressure. Arch Ophthalmol. 1987;105(8):1072–1075
  124. Wilensky JT, Zeimer RC, Gieser DK, et al. The effects of glaucoma filtering surgery on the variability of diurnal intraocular pressure. Trans Am Ophthalmol Soc. 1994;92:377–381discussion 81–3
  125. Wilson MW, Quinn GE, Ling GS, et al. The relation of axial length and intraocular pressure fluctuations in human eyes. Invest Ophthalmol Vis Sci. 2006;47(5):1778–1784
  126. Yang YC, Illango B, Cook M. Intraocular pressure and pulse rate measurements by the OBF tonograph—comparison to reference instruments. Ophthalmic Physiol Opt. 2000;20(5):401–407
  127. Zeimer RC, Wilensky JT, Gieser DK, et al. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology. 1991;98(1):64–69
  128. Zeimer RC, Wilensky JT, Gieser DK, et al. Application of a self-tonometer to home tonometry. Arch Ophthalmol. 1986;104(1):49–53
  129. Zeimer RC, Wilensky JT, Gieser DK, et al. Evaluation of a self tonometer for home use. Arch Ophthalmol. 1983;101(11):1791–1793
  130. Zeppieri M, Brusini P, Miglior S. Corneal thickness and functional damage in patients with ocular hypertension. Eur J Ophthalmol. 2005;15(2):196–201

 Dr. Sultan is an employee of Pfizer Inc. Dr. Mansberger is a consultant and has received research funds and honoraria from Pfizer, Allergan, and Alcon. He has also received honoraria from Heidelberg Engineering. Dr. Lee is a consultant for Alcon, Allergan, Genentech, and Pfizer, a guest lecturer for Allergan, Merck, and Pfizer, has equity in Merck and Pfizer, has received research support from Pfizer, Allergan, Alcon, and Genentech, and has patents held by Duke University Eye Center. Editorial support, including literature review, revising the paper based on author feedback, and styling the paper for journal submission, was provided by Dr. Diann Glickman of Zola Associates and was funded by Pfizer Inc.

PII: S0039-6257(09)00116-7

doi: 10.1016/j.survophthal.2009.05.001

Survey of Ophthalmology
Volume 54, Issue 6 , Pages 643-662 , November 2009

Article Tools